Wednesday 28 November 2012 – Economic Tribune
The study “Global Pharmaceutical Companies: Rocky Road to Recovery”, published by Fitch Ratings, signals a phase of decline up to 2015 after a period of great expansion in the 1990s. According to the study, the industry is by now mature and incapable of expressing the constant growth levels of 6% in previous years, also following the loss of the patents of some medicines which are particularly well-known among buyers. Fitch identifies emerging markets such as Brazil, China, India, Mexico, Turkey, South Korea and Russia alone will account for 30% of the global drug market while developed markets will only account for 57%. At an industrial level, there will be an increasing number of their aggregation and further, small acquisitions especially in the biotechnology branch. After 2015, the adjustment phase should consolidate and growth should resume thanks, in part, to the new markets. (ICE PARIS)
